8-K: Denali Therapeutics' ALS Drug Fails Primary Endpoint in Phase 2 Trial, Multiple Sclerosis Study Continues

Denali Therapeutics' strategic partner, Sanofi, reported that the Phase 2 HIMALAYA study of SAR443820/DNL788 for amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint, while a separate study for multiple sclerosis will continue.

Summary

• Denali Therapeutics announced that the Phase 2 HIMALAYA study for their drug SAR443820/DNL788, being co-developed with Sanofi, did not meet its primary endpoint in patients with amyotrophic lateral sclerosis (ALS).
• The primary endpoint was measured by the change in the ALS Functional Rating Scale-Revised (ALSFRS-R).
• Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
• The drug, SAR443820/DNL788, is an investigational oral brain-penetrant RIPK1 inhibitor.
• Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis.

Sentiment

Score: 3

Explanation: The failure of the Phase 2 ALS trial is a significant negative, overshadowing the continuation of the multiple sclerosis study. This news is likely to negatively impact investor sentiment.

Positives

• Sanofi will continue the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis.
• Detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study will be presented at a future scientific forum.

Negatives

• The Phase 2 HIMALAYA study of SAR443820/DNL788 for ALS did not meet its primary endpoint, indicating a failure in the trial's main objective.

Risks

• The failure of the ALS study may negatively impact investor confidence in the drug's potential.
• There is a risk that the multiple sclerosis study may also face challenges or not meet its endpoints.
• Future clinical trials may be required, which could increase costs and delay potential market entry.

Future Outlook

Denali and Sanofi will continue the Phase 2 study of SAR443820/DNL788 in multiple sclerosis, and Sanofi will present the detailed results of the failed ALS study at a future scientific forum. The company's future reports to the SEC will provide further updates.

Management Comments

• Denali Therapeutics was informed by its strategic partner Sanofi that the Phase 2 HIMALAYA study evaluating SAR443820/DNL788 in participants with amyotrophic lateral sclerosis (ALS) did not meet the primary endpoint.
• Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
• Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis.

Industry Context

The failure of the ALS trial highlights the challenges in developing effective treatments for neurodegenerative diseases. The continued study in multiple sclerosis indicates a focus on other potential applications for the drug. This news may impact the perception of other companies developing similar treatments.

Comparison to Industry Standards

• The failure of the Phase 2 trial for ALS is a setback, as many companies are actively pursuing treatments for this disease, including Biogen with Tofersen and Amylyx Pharmaceuticals with Relyvrio.
• The continuation of the multiple sclerosis trial is in line with the industry's focus on developing treatments for autoimmune diseases, with companies like Roche (Ocrevus) and Novartis (Kesimpta) having established products in this space.
• The lack of success in the ALS trial may lead to a re-evaluation of the RIPK1 inhibitor approach, while the multiple sclerosis trial will be closely watched to see if it can achieve better results.

Stakeholder Impact

• Shareholders may experience a negative impact on the stock price due to the failed ALS trial.
• Patients with ALS may be disappointed by the lack of positive results from this trial.
• Employees may face uncertainty regarding the future of the ALS program.
• Sanofi, as a strategic partner, will need to reassess the future of the ALS program.

Next Steps

• Sanofi will present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
• Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis.
• Denali will file future reports with the SEC.

Key Dates

Keywords

ALS, amyotrophic lateral sclerosis, SAR443820, DNL788, RIPK1 inhibitor, clinical trial, Phase 2, multiple sclerosis, Sanofi, HIMALAYA study, K2 study